Warfarin reversal: Consensus guidelines, on behalf of the Australasian society of thrombosis and haemostasis (multiple letters) [3]

Medical Journal of Australia

Volumn 182, Issue 7, 2005, Pages 365-368

  Blacker, David J ^a   Dear, Anthony E ^b   Gray, Faye ^b   Byron, Keith ^b   Lubicz, Serge ^c   Kamien, Max ^d   Salem, Hatem H ^e  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b GRIBBLES PATHOLOGY   (Australia)

^c EPWORTH HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; HEPARIN; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

AFRICAN AMERICAN; ANTICOAGULANT THERAPY; AUSTRALIA; BLEEDING DISORDER; CAUCASIAN; CONSENSUS; ENDOSCOPY; ENZYME ACTIVITY; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; LETTER; MEDICAL SOCIETY; PATIENT CARE; POPULATION RESEARCH; PRACTICE GUIDELINE; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; THROMBOSIS; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG MONITORING;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; GENE FREQUENCY; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; WARFARIN; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG MONITORING; ENDOSCOPY; PRACTICE GUIDELINES; THROMBOEMBOLISM;

EID: 21444442072     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb06741.x     Document Type: Letter

References (0)